Luye Pharma Group Ltd. (HKG:2186)
1.920
+0.010 (0.52%)
Jul 10, 2026, 4:08 PM HKT
Luye Pharma Group Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Luye Pharma Group stock has a consensus rating of "Buy" and an average price target of $3.52. The average 1-year stock price forecast is 83.33% higher than the current stock price, while the lowest is $2.71 (+41.15%) and the highest is $4.33 (+125.52%).
Price Target: $3.52 (+83.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Luye Pharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | Jul '25 | Sep '25 | Dec '25 | Feb '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst SDIC Securities No rating | SDIC Securities | Buy Maintains $4.34 → $4.14 | Buy | Maintains | $4.34 → $4.14 | +115.63% | Jun 18, 2026 |
Unknown Analyst Citi No rating | Citi | Buy Maintains $4.30 | Buy | Maintains | $4.30 | +123.96% | Apr 13, 2026 |
Financial Forecast
Revenue This Year
6.82B
from 6.31B
Increased by 8.17%
Revenue Next Year
7.33B
from 6.82B
Increased by 7.45%
EPS This Year
n/a
EPS Next Year
n/a
Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 7.2B | ||
| Avg | 6.8B | ||
| Low | 6.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.6% | ||
| Avg | 8.2% | ||
| Low | 2.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |